Does elevated ADMA inhibit nitric oxide synthase and contribute to endothelial dysfunction?

Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) serve as critical, distinct biomarkers of vascular health and organ clearance, offering precise insights into nitric oxide pathways and renal function.

Mechanistic pathways of endothelial dysfunction

• Enzymatic inhibition: ADMA acts as a potent, competitive inhibitor of nitric oxide synthase (NOS) isoforms, particularly eNOS and nNOS, with an in vitro half-maximal inhibitory concentration (IC50) of 2 to 3 μM and an inhibition constant (Ki) of 3.9 μM.
• Reduced nitric oxide (NO) bioavailability: By displacing L-arginine, elevated ADMA suppresses the synthesis of NO, which is essential for regulating vascular tone, inhibiting platelet aggregation, and preventing leukocyte adhesion.
• Vascular impairment: This loss of NO directly drives endothelial dysfunction. Clinical studies demonstrate a strong negative correlation (r = -0.7 to -0.8) between circulating ADMA levels and flow-mediated dilation (FMD), making elevated ADMA an independent predictor of cardiovascular mortality.

Clearance dynamics and clinical interpretation

• Divergent elimination pathways: ADMA is primarily (70–90%) metabolized by dimethylarginine dimethylaminohydrolase (DDAH). In contrast, SDMA is not a substrate for DDAH and relies almost exclusively on renal excretion.
• Indicator of renal function: Because SDMA concentration is highly sensitive to the glomerular filtration rate (GFR)—typically rising when GFR decreases by 25–40%—a normal plasma SDMA level is a reliable indicator of healthy renal clearance.
• Ruling out clearance deficits: A normal SDMA concentration clinically reduces concern for generalized or systemic clearance impairments that would otherwise cause methylated arginines to accumulate.

Bottom line

• Bottom line: Elevated ADMA directly drives endothelial dysfunction by competitively inhibiting NOS and reducing nitric oxide availability, while a normal SDMA level clinically rules out generalized renal clearance deficits as a cause of dimethylarginine accumulation.